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ABSTRACT
Atherosclerosis underlies many cardiovascular and cerebrovascular diseases. Nutraceuticals are
emerging as a therapeutic moiety for restoring vascular health. Unlike small-molecule drugs, the
complexity of ingredients in nutraceuticals often confounds evaluation of their efficacy in preclin-
ical evaluation. It is recognized that the liver is a vital organ in processing complex compounds into
bioactive metabolites. In this work, we developed a coculture system of human pluripotent stem
cell-derived endothelial cells (hPSC-ECs) and human pluripotent stem cell-derived hepatocytes
(hPSC-HEPs) for predicting vascular-protective effects of nutraceuticals. To validate our model,
two compounds (quercetin and genistein), known to have anti-inflammatory effects on vascula-
tures, were selected. We found that both quercetin and genistein were ineffective at suppressing
inflammatory activation by interleukin-1b owing to limited metabolic activity of hPSC-ECs. Conversely,
hPSC-HEPs demonstrated metabolic capacity to break down both nutraceuticals into primary and sec-
ondary metabolites. When hPSC-HEPs were cocultured with hPSC-ECs to permit paracrine interactions,
the continuous turnover ofmetabolitesmitigated interleukin-1b stimulation on hPSC-ECs.Weobserved
significant reductions in inflammatory gene expressions, nuclear translocation of nuclear factorkB, and
interleukin-8 production. Thus, integration of hPSC-HEPs could accurately reproduce systemic effects in-
volved in drug metabolism in vivo to unravel beneficial constituents in nutraceuticals. This phys-
iologically relevant endothelial-hepatic platform would be a great resource in predicting the
efficacy of complex nutraceuticals and mechanistic interrogation of vascular-targeting candidate
compounds. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–13
SIGNIFICANCE
Blood vessel diseases underlie a spectrumof debilitating conditions. Nutrition and biologics are increas-
ingly being explored as a strategy to restore vascular health. Unlike the traditional small-molecule drugs,
the complexity of constituents innutraceuticals presents challenges inpredicting their potency in animal
testing. This article describes the first human stem cell-based vascular-liver coculture system that allows
metabolismofnutraceuticals into their vascular-protective ingredients. Thiswork is significantonseveral
fronts. The liver component enables processing of complex nutraceuticals intometabolites, which exert
anti-inflammatory effects on the vascular cells. This system could facilitate testing of new drugs with
human-relevant metabolic profiles. These findings will have great impact on drug development and
broad applications in studying diseases implicating vascular-liver paracrine interaction.
INTRODUCTION
Cardiovascular diseases and stroke, which are
among the top causes of mortality, pose major
health care burdens. Common risk factors such as
high blood pressure and hypercholesterolemia un-
derscore a predisposition to blood vessel dysfunc-
tion. Atherosclerosis, characterized by arterial
hardening and fatty plaque build-up in vessel walls,
is oneof thekeycontributors to vascularpathology.
It is multifactorial, involving many cell types in a
complex interplay of inflammation and oxidative
stress [1]. Long-term medication is often required
for secondary prevention of adverse vascular
events. Despite beneficial pleiotropic effects of
cholesterol-lowering statins on the vasculature,
other side effects have been reported [2]. The con-
ceptofmedical nutrition ison the rise tohelpmod-
ulate chronic diseases [3]. Dietary phospholipids
from soybean, eggs, and fish have been explored
as nutraceuticals with protective effects on ath-
erosclerosis [4]. Herbal extracts are used as
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antiatherogenic agents by reducing the production, absorption,
or oxidation of cholesterol [5, 6]. Unlike small-molecule drugs,
the complexity of constituents in nutraceuticals often present
challenges in predicting their efficacy in preclinical screening.
The liver is integral to biotransformation of complex compounds
into new chemical species that may confer either therapeutic or
toxic effects. Therefore, a human-relevant vascularmodel that in-
corporates livermetabolismwould bemore effective in assessing
bioactivity of nutraceutical ingredients.
Advances in humanpluripotent stemcell (hPSC) differentiation
offer an unparalleled ability to generate many cell types in ade-
quate quantities for tissue engineering, regenerative medicine,
anddiseasemodeling in vitro [7–9]. Vascular cell-basedphenotypic
assays have been demonstrated using endothelial and smooth-
muscle cells generated from hPSCs [10–12]. In response to inflam-
matoryorbiomechanical stimuli,hPSC-derivedendothelial cellsare
able tomodel athero-susceptible phenotypes and display a breach
of barrier integrity to allow leukocyte transmigration. Although in-
corporation of primary hepatocytes is most likely to replicate hu-
man liver function for drug testing in a metabolism-enabled
cellular model, their scarcity and the high cost of freshly isolated
or cryopreserved human primary hepatocytes limit their extensive
use [13]. We and others have created hPSC-derived hepatocytes
that express cytochrome P450 (CYP) drug-metabolizing enzymes
and show sensitivity to drugs with known hepatotoxicity [14,
15]. Interestingly, induced hepatocytes derived directly by lineage
reprogramming of human fibroblasts have comparable CYP activi-
ties with primary hepatocytes [16]. Vascularized liver microtissue
has been proposed, although its utility as a drug-testing platform
has not yet been shown [17]. Thus far, there has not been amodel
developed to recapitulate vasculature-liver paracrine interaction
for efficacy testing of complex compounds.
In thiswork,wedevelopedavascular-livermodelbasedonhPSC-
derived endothelial cells (hPSC-ECs) and hPSC-derived hepatocytes
(hPSC-HEPs). The hPSC-ECs, generated via a mesodermal precursor
population,demonstratedfunctionalcharacteristicssuchas tubefor-
mation and inflammatory activation.HPSC-HEPswere derivedbyus-
ingourpreviousprotocol [18],andtheyexpresseddrug-metabolizing
enzymes. To test our hypothesis, we selected two nutraceuticals,
quercetin and genistein, that are known to have potential
vascular-protective effects [19, 20].We found that the parent com-
pounds elicited minimal anti-inflammatory effects on hPSC-ECs.
Conversely, when cocultured with hPSC-HEPs, the inflammatory
response of hPSC-ECs was suppressed effectively, suggesting nutra-
ceutical bioactivation by the metabolic activity of hepatocytes. Our
data support thehypothesis that hPSC-HEPs couldprocess quercetin
and genistein into primary and secondary metabolites, which
exerted greater anti-inflammatory effects compared with their
parent compounds. Hence, this hPSC-based endothelial-hepatic
platform could better predict the efficacy of nutraceuticals and
identify beneficial properties of their constituent ingredients.
MATERIALS AND METHODS
HPSC Culture and Maintenance
HPSCs were passaged by using a gentle cell dissociation agent
(StemCell Technologies, Vancouver, BC, Canada, http://www.
stemcell.com, catalog no. 07174) and seeded onto Matrigel-
coatedplates inmTeSR1medium (StemCell Technologies, catalog
no. 05850). WA09 human embryonic stem cells (H9-ESCs) and
iPSCs derived from IMR90 fibroblasts (IMR90-iPSCs) were purchased
fromWiCell (Madison,WI, http://www.wicell.org). iPSCs derived from
BJ fibroblasts (BJ-iPSCs) were kindly provided by a collaborator’s
laboratory.
Generation of Endothelial Cells From hPSCs
After the hPSC colonies attached, they were first induced to drive
early mesoderm differentiation for 36 hours, by using a chemi-
cally defined medium, supplemented with human recombinant
fibroblast growth factor 2 (FGF2) (20 ng/ml, R&D Systems, Min-
neapolis, MN, https://www.rndsystems.com, catalog no. 233-
FB), LY294002 (10 mM, Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com, catalog no. L9908), and human recombi-
nant bone morphogenetic protein 4 (BMP4) (10 ng/ml, R&D Sys-
tems, catalog no. 314-BP) [21]. Lateral plate mesoderm was
further induced for another 3.5 days in medium supplemented
with human recombinant FGF2 (20 ng/ml) and BMP4 (50 ng/ml),
withmedium change every 2 days. On day 5, the lateral plateme-
soderm population was trypsinized by using TrypLE Express
(Thermo Fisher Scientific Life Sciences, Oakwood Village, OH,
https://www.thermofisher.com, catalog no. 12604) and plated
on Matrigel-coated plates in the same basal medium supple-
mented with FGF2 (4 ng/ml), SB431542 (10 mM, Sigma-Aldrich,
catalog no. S4317), and vascular endothelial growth factor (VEGF)
(50 ng/ml, R&D Systems, catalog no. 293-VE) with medium
change every 2–3 days. On day 10, platelet and endothelial cell
adhesionmolecule 1 (PECAM1)-expressing endothelial cells were
sorted by using fluorescence-activated cell sorting with PECAM1
antibody (BioLegend, San Diego, http://www.biolegend.com,
catalog no.303110). The PECAM1+ cells were plated at a density
of 5 3 104 per cm2 onto collagen I-coated plates in commercial
medium EGM-2 (Lonza, Walkersville, MD, http://www.lonza.
com, catalog no. CC-3162). hPSC-ECs were passaged by using
TrypLEExpresswhen they reachedmore than75%confluence. Fresh
complete EGM-2 medium was replaced every 2–3 days. All exper-
iments were performed on cells up to passage 10. In this work,
hPSC-ECs derived from three different cell lines—H9-ESCs (Figs.
1–5), IMR90-iPSCs, and BJ-iPSCs (supplemental online Figs. 2
and 3)—were functionally characterized and used in inflamma-
tory activation assays. In EC marker and functional characteriza-
tion, human coronary artery ECs (HCAECs) were used as positive
control, whereas HeLa cells and human hepatocellular carcinoma
cells (HUH7) were used as negative controls.
Generation of Hepatocytes From hPSCs
Hepatocytes were generated from hPSCs by a growth factor-
based differentiation protocol described in our previous protocol
[15]. After 20 days of differentiation, the cells were harvested by
using a serial 23 TrypLE Express treatment and further dissoci-
ated into single cells by passing them through a 40-mm cell
strainer. These single cells were then seeded at 2.5 3 105 cells
per well in a collagen I (50 mg/ml, Bio Laboratories, Singapore,
http://www.biolab.com.sg, catalog no. 354236)-coated dishes.
Attachment and recoverywerepromotedby seeding them in step
IV differentiation medium with hepatocyte growth factor (R&D
Systems, catalog no. 294-HGN-005), Follistatin (R&D Systems,
catalog no. FS-288), Oncostatin (R&D Systems, catalog no. 295-
OM-010), and Y-27632 (Rock Inhibitor) to prevent anoikis in the
freshly harvested hPSC-HEPs. The next day, medium was changed
to Williams E medium (Sigma-Aldrich, catalog no. W1878) without
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Figure 1. Generation and characterization of functional endothelial cells from human embryonic stem cells. (A): Timeline of endothelial induction
fromhPSC, delineating the differentiationmedia and factors used. HPSC-ECswere derived via a lateral platemesodermpopulation on day 5. By day
10, PECAM1-expressing cells could be isolated and expanded further. (B): Flow-cytometric analysis demonstrating that 1% O2 promoted higher
percentages of PECAM1-expressing cells than 21% O2, during endothelial induction from day 5 onward. ppp, p , .001 (compared with 21% O2;
n = 3 independent biological replicates). (C): Flow cytometric contour plots on the purity of PECAM1-expressing cells after FACS. (D):Western blot
(Figure legend continues on next page.)
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serum,andcellswereserum-starvedovernightbeforenutraceutical
treatments. Nutraceuticals quercetin (Sigma-Aldrich, catalog no.
Q4951) and genistein (Sigma-Aldrich, catalog no. G6649) were ad-
ministered at a single doseof10mM.Hepatocytes in thisworkwere
derived from H9-ESCs. In hepatic characterization, primary human
hepatocytes (PHHs) and HUH7 cells were used as positive controls,
and HeLa cells were used as negative controls.
HPSC-HEP-ConditionedMedia Experiments onhPSC-ECs
HPSC-HEPs (1.253 105 cells per cm2)were cultured for 48 hour in
1:1William’s Emedium+EGM-2without serumcontaining10mM
quercetin [22–25] or 10 mM genistein [22, 26–31]. Conditioned
medium from hPSC-HEPs treated with quercetin or genistein
wascollectedandaddedtohPSC-ECs (thatwereserum-starvedover-
night) along with 20 ng/ml interleukin-1b (IL-1b) for determination
of nuclear factor kB (NFkB) nuclear colocalization (at 1 hour), gene
expressionprofileof inflammatorymarkers (at6hours), and IL-8pro-
tein levels (1 day) upon inflammation.
Endothelial-Hepatocyte Coculture Experiments on Ibidi
2 3 9 Wells
H9-ESCs were used to generate the ECs and hepatocytes for co-
culture experiments and assays with nutraceuticals. Both cell
types were derived from an isogenic source of hPSCs to ensure
a robust endothelial-hepatic model without confounding pheno-
typic differences due to genetic variations. The Ibidim-slide 23 9
Figure 2. Inflammatory activationofH9-embryonic stemcell-derived endothelial cells by IL-1b. (A):Upregulation of inflammatory genes in human
pluripotent stem cell-derived endothelial cells (hPSC-ECs) stimulated by IL-1b (20 ng/ml) for 6 hours. (B): Immunostaining of NFkB showed nuclear
translocation in hPSC-ECs after IL-1b (20 ng/ml) for 1 hour. Scale bars = 100 mm. (C): Enzyme-linked immunosorbent assay quantification of IL-8
concentrations in conditionedmedia of IL-1b-stimulated hPSC-ECs. p, p # .05; pp, p # .01; ppp, p # .001 (compared with their respective unsti-
mulated controls; n = 3 independent biological replicates). Abbreviations: IL, interleukin; NFkB1, nuclear factor kB1.
(Figure legend continued from previous page.)
staining for CDH5protein in cell lysates of hPSC-ECs andHCAEC. (E): Immunostaining for endothelialmarker vWF inhPSC-ECs,HCAEC (positive
control) andHeLa cells (negative controls). (F): Immunostainingfor functionalmarkereNOS inhPSC-ECs,HCAEC,andHUH7cells (negativecontrol).
(G): Uptake of 3,3’-dioctadecyloxacarbocyanine-labeled acetylated-LDL in hPSC-ECs, HCAECs, and HeLa cells. Scale bars = 100 mm. (Hi): Phase con-
trast images of tube formation at 3 hour postseeding. Scale bars = 500mm. (Hii): Quantification of tube forming capability of cells. ppp, p # .001
relative to HeLa; ##, p # .01 relative to HCAEC (n = 3 independent biological replicates). Abbreviations: BMP4, bone morphogenetic protein 4;
EC, endothelial cell; eNOS, endothelial nitric oxide synthase; FACS, fluorescence-activated cell sorting; FGF2, fibroblast growth factor 2; HCAEC, hu-
man coronary artery endothelial cell; hPSC, human pluripotent stem cell; hPSC-EC, human pluripotent stem cell-derived endothelial cell; HUH7,
humanhepatocellular carcinoma cells; LDL, low-density lipoprotein; LY294002, phosphoinositide 3-kinase inhibitor; PECAM1, platelet and endothe-
lial cell adhesion molecule 1; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.
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Figure 3. Quercetin and genistein are unable to suppress IL-1b-induced inflammation in H9-embryonic stem cell-derived endothelial cells (ECs).
(A): Gene expression of inflammatory markers in IL-1b-stimulated human pluripotent stem cell-derived endothelial cells (hPSC-ECs) treated with
quercetin and genistein over time. (Bi): Immunostaining for NFkB in unstimulated and IL-1b-stimulated hPSC-ECs, treated with or without quer-
cetin and genistein. Scale bars = 100 mm. (Bii): Quantification of nuclear colocalization levels of NFkB by Pearson’s coefficient. ppp, p # .001
(comparedwith their respective unstimulated controls; n = 3 independent biological replicates). (C): Enzyme-linked immunosorbent assay
(Figure legend continues on next page.)
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wells (Ibidi, Martinsried, Germany, http://ibidi.com) were used
for creating the coculture setup. Eachminor well was first coated
with collagen I, and then a total of 2.53 105 hPSC-ECs and hPSC-
HEPs were seeded in individual wells in a 1:1 ratio [32] within a
major well to allow equivalent contribution of paracrine factors
between the two cell types (Fig. 5A). After cell attachment, the
medium was changed to 1:1 William’s E and EGM-2 without se-
rum, to be commonly shared by hPSC-ECs and hPSC-HEPs in ama-
jor well. Upon overnight serum starvation, the cocultures were
preconditioned with 10 mM quercetin or genistein for 48 hours
before IL-1b stimulation.
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was prepared by using an RNeasy mini kit (Qiagen, Hil-
den, Germany, http://www.qiagen.com, catalog no. 74104). Each
RNA sample (250 ng) was reverse-transcribed into cDNA by using
theMaxima First Strand cDNA Synthesis kit (Thermo Fisher Scien-
tific, catalog no. K1641). Quantitative polymerase chain reaction
was performed on a StepOnePlus Real-Time PCR system (Thermo
Fisher) by using FAST SYBR greenmaster mix (Thermo Fisher, cat-
alog no. 4385616). Expression levels were normalized to the
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase.
Refer to supplemental online Table 1 for primer sequences.
Flow Cytometry
Cells were trypsinized and stained by using 5 ml of anti-human
CD31 antibody (BioLegend, catalog no. 303110) diluted in 80 ml
of phosphate-buffered saline (PBS) with 20% fetal bovine serum
(FBS) per 106 cells, for 1 hour at 4°C, afterwhich cold PBSwasused
towash the cells. The cell pelletwas collected by centrifugation at
200g for 3 minutes. The cell pellet was resuspended in 350 ml of
PBSwith 20%FBS for sorting. PECAM1+ cellswere sorted by using
a FACSAria IIu SORP cell sorter (BD Biosciences, San Jose, CA,
http://www.bdbiosciences.com) and collected in PBS containing
20% FBS.
Immunocytochemistry
Cells were fixedwith 4%paraformaldehyde (Nacalai Tesque, Kyoto,
Japan, http://www.nacalai.co.jp, catalog no. 09154-14) and per-
meabilized by 0.5% Triton X-100 (Acros Organics, Geel, Belgium,
http://www.acros.com, catalog no. 215680010) in PBS with Ca2+
and Mg2+ at room temperature. Blocking was performed by using
PBS with 10% serum overnight at 4°C. Cells were incubated with
the respective primary antibody diluted in 0.1% serum containing
PBS for 1 hour and secondary antibodies in 0.1% serum containing
PBS for another hour.Washeswere performed twice using 0.1% se-
rum containing PBS. The 49,6-diamidino-2-phenylindole (1 mg/ml,
ThermoFisher, catalogno.D3571)wasused to stain the cell nucleus
for 10minutes. Refer to supplemental online Table 2 for details for
primary antibodies used.
Tube Formation Assay
Matrigel-coatedplates for tube formationwerepreparedbyadding
50 ml of Matrigel (10 mg/ml, BD Biosciences, catalog no. 356234)
per well of a 96-well plate and incubated at 37°C for 30 minutes.
Cells were trypsinized and plated at a density of 9.3 3 104 cells
per cm2 in 150 ml of complete EGM-2 per well. Images were taken
hourly by using an invertedmicroscope (Olympus, Shinjuku, Tokyo,
http://www.olympus-global.com, CKX41) at 35 magnification.
Quantitative analysis of tube characteristics was performed by
WimTube image processing online software (Wimasis Image Anal-
ysis, Co´rdoba, Spain, http://www.wimasis.com).
Acetylated Low-Density Lipoprotein Uptake Assay
The 3,3’-dioctadecyloxacarbocyanine acetylated low-density
lipoprotein (Biomedical Technologies, Villalba, Spain, http://
www.biomedical-technologies.com, catalog no. BT-925) was di-
luted in complete EGM-2 at a concentration of 10 mg/ml before
incubation with hPSC-ECs at 37°C with 5% CO2 for 4 hours. The
cells were visualized and imaged by using an Olympus Fluoview
inverted confocal microscope at 320 magnification.
Enzyme-Linked Immunosorbent Assay
Conditioned EGM-2 medium was collected, and the concen-
tration of human IL-8 was determined by using the human IL-8
enzyme-linked immunosorbent assay (ELISA) kit (Thermo
Fisher, catalog no. KHC0081), according to the manufacturer’s
instructions.
Western Blot
The cell lysates were collected by using radioimmunoprecipita-
tion assay buffer (Thermo Fisher, catalog no. 89901) containing
13 proteinase inhibitor cocktail (Sigma-Aldrich, catalog no.
P8340). Protein quantification was performed by using the
Quant-iT protein assay kit (Thermo Fisher, catalog no. Q32210).
A total of 80 mg of cell lysates was separated by NuPAGE 10%
Bis-Tris Gel (Thermo Fisher, catalog no. NP0303BOX) and trans-
ferred onto a nitrocellulose membrane. MagicMark XP Western
protein standard (Thermo Fisher, catalog no. LC5602) was used
todetermine themolecularweightofproteinbands. TheWesternDot
625 goat anti-rabbit Western blot kit (Thermo Fisher, catalog no.
W10142) was used to visualize the protein bands. Blocking was per-
formedat4°Covernightbyusing3%skimmedmilk in13washbuffer
provided by the kit and stained with CDH5 antibody in 3% skimmed
milksolutionfor1houratroomtemperature.Theproteinbandswere
visualized and imaged by using Bio-Rad ChemiDoc MP Imaging Sys-
tem (Bio-Rad, Hercules, CA, http://www.bio-rad.com).
Liquid Chromatography-Mass Spectrometry
The metabolic potential of the hPSC-HEPs and primary rat hepa-
tocytes (freshly isolated according to our previously established
protocol [33]) were tested by exposing them to nutraceuticals
(Figure legend continued from previous page.)
quantification of IL-8 concentrations in conditionedmedia of IL-1b-stimulated hPSC-ECs, treated with or without quercetin and genistein for
48 hours. (D, E): Liquid chromatography-mass spectrometry analysis of metabolic profiles of parent nutraceuticals, quercetin (blue line) and
genistein (green line) by hPSC-ECs. Primary and secondarymetabolites of nutraceuticalswere indicated by black lines. p, p # .05; pp, p # .01
(compared with their respective 6-hour time points; n = 3 independent biological replicates). Abbreviations: IL, interleukin; IS, internal stan-
dard; NFkB, nuclear factor kB.
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Figure 4. H9-embryonic stem cell-derived hepatocytes (HEPs) are able to effectively metabolize nutraceuticals. (A): Immunocytochemistry
showing presence of albumin in hPSC-HEPs and HUH7 cells (positive control), but not in HeLa cells (negative control). Scale bars = 200 mm.
(B): Characterization of cytochrome P450 gene expression in hPSC-HEPs, PHH (positive control), and hPSC (negative control). (C, D): Liquid chro-
matography-mass spectrometry analysis of metabolic profiles of parent nutraceuticals, quercetin (blue line) and genistein (green line) by
hPSC-HEPs. The production of primary and secondary metabolites of nutraceuticals (indicated by black lines) increased with time. p, p # .05;
pp,p # .01 (comparedwith their respective6-hour timepoints;n=3 independentbiological replicates). (E):Geneexpression levelsof inflammatory
(Figure legend continues on next page.)
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quercetin and genistein (10 mM) over different durations. Inter-
nal standard (IS) (Emodin, 10 ng/ml) was added to the conditioned
medium. The solid-phase extraction column (Phenomenex, Tor-
rance, CA, https://www.phenomenex.com, Strata C18-E, 55 mm,
70A) was conditioned by washing with 1 ml of methanol and then
2 ml of deionized water. Conditioned medium was added into the
column, and 1.5 ml of 30%methanol was added to elute the impu-
rity such as phenol red in the medium. 0.1% formic acid methanol
was added to the column to elute all the metabolites and internal
standard out to a 15-ml tube. Liquid in the 15-ml tubewas dried un-
der N2 in a sample concentrator with 30°C heater. After drying the
sample, 100 ml of 0.1% formic acid methanol was added to the
15-ml tube and vortex for 30 seconds and transferred to another
1.5-ml tube. The samples were then centrifuged at 13,000 rpm
for 10 minutes at 4°C, and 10 ml of the supernatant was injected
into liquid chromatography-mass spectrometry (LC-MS). High-
performance liquid chromatography combined with electrospray
ionization (ESI) iontraptime-of-flight (IT-TOF)multistagemassspec-
trometry analyses were performed with a Shimadzu LC-MS-IT-TOF
instrument, which was composed of two LC-20AD pumps, a SIL-
20AC autosampler, a CTO-20A column oven, a CBM-20A system
controller, an ESI ion source, and an IT-TOFmass spectrometer (Shi-
madzu, Kyoto, Japan, http://www.shimadzu.com).
Statistical Analysis
Datawere expressed as mean6 SD of at least three biological rep-
licates of independent experiments. Statistical comparisons were
conducted by Student’s unpaired t test with 95% confidence inter-
val for two groups of samples or one-way analysis of variance with
Bonferroni’s post hoc test in multiple group comparisons. Analyses
were carried out with GraphPad Prism 5 software (GraphPad Soft-
ware Inc., La Jolla, CA, http://www.graphpad.com).
RESULTS
Derivation of Functional Endothelial Cells From Human
Pluripotent Stem Cells
Lateral plate mesoderm is a precursor tissue of vascular lineages.
We adopted our established protocol of using fibroblast growth
factor 2, bone morphogenetic protein 4, and phosphoinositide
3-kinase inhibitor (LY294002) to induce lateral plate mesoderm
for 5 days [21] (Fig. 1A). We then used a combination of factors
to drive endothelial specification. Transforming growth factor
b (TGF-b) inhibition using small molecule SB431542 has been
shown to enhance endothelial differentiation of hPSCs [34, 35],
possibly by counteracting growth ofmural cells, which could arise
from a common cardiovascular progenitor. FGF2 and vascular en-
dothelial growth factor are commonly known mitogens for pro-
moting angiogenesis and endothelial development [36, 37].
Studies have also shown that hypoxic conditions increase the
efficiency of endothelial differentiation [38, 39], because upregu-
lation of hypoxia-inducible factor triggers downstream targets
that play an important role in early blood vessel development
[40]. To induce endothelial differentiation, the day 5 mesodermal
populationwas dissociated and plated down as single cells.We cul-
tured these cells under 1% oxygen (O2) in a chemically definedme-
dium containing SB431542, FGF2, and VEGF (Fig. 1A). Endothelial
genes were significantly enhanced in 1% O2 as compared with
21% O2, peaking primarily at approximately day 10 (supplemental
online Fig. 1A). Flow-cytometric analysis further supported that
endothelial specification was optimal at approximately day 10
in 1% O2, with more than 45% of the cells positive for PECAM1
(Fig. 1B; supplemental online Fig. 1B). This protocol generated a
sufficient yield of PECAM1+ cells for cell sorting on day 10 of dif-
ferentiation, giving rise to a purity of 98.43 6 0.16% (Fig. 1C).
This PECAM1+ population was then grown on collagen I coating
and expanded by using a commercial endothelial growthmedia
(EGM-2). We hereafter refer to these cells as hPSC-ECs.
Western blot demonstrated the presence of endothelial
adherens junctions, CDH5, in hPSC-ECs and the positive control,
human coronary artery endothelial cells (Fig. 1D). Different glyco-
sylated forms of CDH5 were found in hPSC-ECs, close to the mo-
lecular weights of those in HCAEC. We postulated that there
might be differences in glycosaminoglycan synthesis enzymes
in hPSC-ECs and HCAECs [41]. Our hPSC-ECs formed spontaneous
tube structures that stained for themature endothelialmarker, von
Willebrand factor (vWF) (Fig. 1E). In addition, hPSC-ECs possessed
endothelial nitric oxide synthase (eNOS) (Fig. 1F) and were capable
of taking up acetylated low-density lipoprotein (LDL) (Fig. 1G), re-
semblingHCAECs,but not thenegative controls.Weobserved com-
parable tube-forming capability between hPSC-ECs and HCAECs
(Fig. 1H). We reproduced this endothelial differentiation protocol
on twoother hPSC lines, namely, the BJ- and IMR90-inducedplurip-
otent stem cells. The BJ- and IMR90-derived ECs also expressed en-
dothelial proteins (supplemental online Fig. 2A, 2B), as well as
demonstrated tube formation capability (supplemental online
Fig. 2C). These functional hPSC-ECs were subsequently used for as-
say development.
HPSC-Derived Endothelial Cells Respond to
Inflammatory Stimulation
Inflammation is a hallmark of atherosclerosis [1]. To recapitulate
atherosclerosis-associated phenotypes in hPSC-ECs, we used an in-
flammatory cytokine, interleukin-1b, which is widely implicated in
atherosclerosis. Upon stimulation with human recombinant IL-1b,
hPSC-ECs responded with a significant upregulation of inflamma-
tory genes (Fig. 2A). Nuclear translocation of nuclear factor kB, ac-
tivating major proinflammatory mediators, has been observed in
human atherosclerotic lesions [42]. Likewise, nuclear translocation
of NFkB was evident in hPSC-ECs after stimulation with IL-1b
(Fig. 2B). The production of interleukin 8 from conditioned media
(Figure legend continued from previous page.)
markers in IL-1b-stimulated hPSC-HEPs upon nutraceutical treatment for 48 hours. Quercetin (blue bar) or genistein treatments (green bar) de-
creasedmost of the inflammatorymarker expression in stimulated hPSC-HEPs. p, p # .05; pp, p # .01; ppp, p # .001 (comparedwith stimulated
groupwithout nutraceutical treatment (black bar);n=3 independentbiological replicates). (F):Enzyme-linked immunosorbentassayquantification
of IL-8 concentrations in conditionedmediaof IL-1b-stimulatedhPSC-HEPs treatedwithorwithoutquercetinandgenistein for48hours.pp,p # .01
(compared with stimulated group without nutraceutical treatment; n = 3 independent biological replicates). Abbreviations: CYP3A4, cytochrome
P450 3A4; hPSC, human pluripotent stem cell; hPSC-HEPs, human pluripotent stem cell-derived hepatocytes; HUH7, human hepatocellular carci-
noma cells; IL, interleukin; IS, internal standard; NFkB1, nuclear factor kB1; PHH, primary human hepatocytes.
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of IL-1b-stimulated hPSC-ECs was significantly higher than that of
the unstimulated cells (Fig. 2C). In addition to H9-ECs, we also val-
idated that BJ-ECs and IMR90-ECs could respond to IL-1b by upre-
gulation of inflammatory genes and increase of NFkB nuclear
translocation, as well as elevated IL-8 production (supplemental
online Fig. 3). Hence, we were able to monitor hPSC-EC inflamma-
tory activation using a range of phenotypic readouts.
Nutraceuticals Are Not Effective in Suppressing the
Inflammatory Response of hPSC-Derived
Endothelial Cells
Next, we testedwhether administration of nutraceuticals quer-
cetin and genistein could suppress inflammatory responses in
IL-1b-stimulatedhPSC-ECs.Quercetin, anaturally occurring flavo-
noid compound, is found commonly in food, such as tea, onions,
berries, and apples. It exerts various beneficial effects through its
anti-inflammatory [19] and antioxidant [43] properties. Quercetin
intake is also correlated with lower incidence of coronary heart
disease and stroke [44]. Genistein, a potent phytoestrogen, is
effective in mitigating endothelial dysfunction [20] and exerts
an anti-inflammatory effect by downregulating the NFkB path-
way [22]. Plasma concentrations for genistein can range from
0.03 to 16.34mM [30, 45], in linewith the dosage commonly used
for invitrostudies [22,26–31].Quercetinhasvery lowbioavailability
inhumanplasma,where the concentrations rangebetween0.3 and
3.5 mM [46–49]. Nonetheless, higher concentrations of quercetin
are known to be safe and well tolerated [50, 51]. Previous studies
in human hepatocytes [24, 25] and human C-reactive proteinmice
[23] have used quercetin at a concentration of 10mM. Therefore,
we chose to treat the stimulated hPSC-ECs with quercetin or gen-
istein at a concentration of 10 mM for up to 72 hours. However,
gene expression of inflammatory markers did not show substan-
tial reduction from the IL-1b-stimulated levels at various time
points (Fig. 3A). NFkB nuclear translocation levels remained ele-
vated despite administration of quercetin and genistein (Fig. 3B).
There was also no significant reduction of IL-8 protein levels from
the conditionedmediaof stimulatedhPSC-ECS after nutraceutical
treatment for 48 hours (Fig. 3C).
Wefurther investigatedwhetherthehPSC-ECscouldmetabolize
the nutraceuticals. By using liquid chromatography-mass spectrom-
etry to analyze conditionedmedia from hPSC-ECs, the level of quer-
cetin (blue line)was found todecreaseover time,whereas the levels
ofmetabolites (black lines) frombothnutraceuticalsdidnot increase
remarkably (Fig. 3D, 3E).Ourdata showed that first, theparent com-
poundsmaynotbeeffectiveatelicitinganti-inflammatoryeffectson
endothelial cells. Second, limited capacity of hPSC-ECs to break
down the nutraceuticals into metabolites could have compro-
mised the bioactivity of these compounds. Therefore, we explored
whether hepatocytes derived from hPSCswere capable of metabo-
lizing the nutraceuticals.
HPSC-Derived Hepatocytes Bioactivate Nutraceuticals
Through Metabolism
Liver has been shown to metabolize quercetin into its bioactive
metabolites, which in turn exert greater beneficial effects com-
pared with their parent compound [24, 25]. We generated hepa-
tocytes from hPSCs following our established protocols [15, 18].
The stepwise differentiation protocol recapitulates embryonic liver
development because hPSCs progressively turn from primitive
streak/mesoendoderm, definitive endoderm, and hepatoblasts to
become hepatocytes (hereafter referred to as hPSC-HEPs). Our
hPSC-HEPs stained positive for albumin, characteristic of functional
hepatocytes (Fig. 4A). Inaccordancewithourprevious findings [15],
we produced hPSC-HEPs that expressed cytochrome P450 genes
(Fig. 4B), some of which were comparable to the positive control
PHH. CYP enzymatic activities are necessary for the metabolism
of complex compounds.
Indeed, LC-MS analysis demonstrated that the levels of both
quercetin (blue line) and genistein (green line) gradually declined
over time in the presence of hPSC-HEPs (Fig. 4C, 4D). Correspond-
ingly, the levels ofmetabolites (black lines) increased over time in
the hPSC-HEPs. Most of the metabolites peaked at 48 hours and
dropped by 72 hours. Thus, hPSC-HEPs were capable of convert-
ing quercetin and genistein into their metabolites, with 48 hours
being the optimal duration based on the metabolic profiles of
these nutraceuticals. When we compared the metabolic activity
of our hPSC-HEPs to freshly isolated primary rat hepatocytes [33],
both demonstrated that quercetin (blue bars) and genistein
(green bars) declined over time, giving rise to metabolites (gray
patternedbars) (supplemental online Fig. 4). Because theprimary
rat hepatocytes could have retained some in vivo characteristics,
their metabolic kinetics was apparently faster because substan-
tial metabolites had emerged by 6 hours of treatment. We then
investigated the effects of nutraceuticals on IL-1b-stimulated
hPSC-HEPs. We observed a significant reduction in the panel of
inflammatory gene expression upon nutraceutical treatment
(Fig. 4E). The production of IL-8 protein from conditioned media
of hPSC-HEPs was also significantly suppressed after treatment
with nutraceuticals for 48 hours (Fig. 4F). Hence, the ability of
hPSC-HEPs to process nutraceuticals into their bioactive metabo-
lites could have resulted in their efficacy in abrogating inflamma-
tory activation.
Renewal of Nutraceutical Metabolites in the Presence
of Hepatocytes Protects Endothelial Cells From
Inflammatory Activation
To enable accurate assessment of complex compounds in vascular
health, we examined two configurations of endothelial-hepatic
paracrine interaction. First, we allowed 48-hour preincubation
of each nutraceutical with hPSC-HEPs for metabolism to take
place (Fig. 5A). Subsequently, hPSC-HEP-conditionedmedia were
collected and treated on hPSC-ECs under IL-1b stimulation. Alter-
natively, we cocultured hPSC-ECs and hPSC-HEPs on IBIDI m-slide
23 9 wells, where each cell type could be seeded separately into
minorwells and shared a commonmediumby filling up themajor
wells (Fig. 5A). The coculturewaspretreatedwith eachnutraceut-
ical for 48 hours, followed by IL-1b stimulation. Our data showed
that hPSC-HEP-conditionedmedia with either quercetin or genis-
tein did not seem to inhibit NFkB nuclear translocation in IL-1b-
stimulated hPSC-ECs (Fig. 5B). In contrast, when cocultured with
hPSC-HEPs, stimulated hPSC-ECs displayed a significant suppres-
sion of NFkB nuclear translocation. Furthermore, the secretion of
IL-8 in the coculture settingwas remarkably decreased, but not in
the conditionedmedia configuration (Fig. 5C). Themetabolitepro-
files of quercetin (blue bar) and genistein (green bar) in each of the
twoconfigurations showed that thereweredetectable levels of var-
ious metabolites (gray bars) in the endothelial-hepatic coculture
(supplemental online Fig. 5B), but not in the conditionedmedia set-
ting (supplemental online Fig. 5A). This supports that the metabo-
lites in hPSC-HEP-conditionedmedia could bedegraded to a certain
Narmada, Goh, Li et al. 9
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extent when they were subsequently treated on hPSC-ECs under
IL-1b stimulation.Thismight leadto insufficientanti-inflammatoryef-
fects. Conversely, we also investigated whether hPSC-ECs could, in
turn, impact the metabolic function of hPSC-HEPs in a coculture set-
ting. It has been reported that endothelial cells could improve he-
patic function [52–55]andprovidesomelevelsofhepatoprotection
from acetaminophen toxicity [56]. In our study, cocultured hPSC-
HEPs had comparable albumin levels with monocultured hPSC-
HEPs (supplemental online Fig. 6A). Notably, there was significant
increase of CYP gene expressions in cocultured hPSC-HEPs
(supplemental online Fig. 6B), suggesting that the presence
of hPSC-ECs could promote metabolic activity in hPSC-HEPs.
Figure 5. Coculture with H9-embryonic stem cell-derived hepatocytes (H9-ESC-HEPs) abrogates inflammatory activation in IL-1b-stimulated H9-
embryonic stem cell-derived endothelial cells (H9-ESC-ECs). (A): Schematics showing two experimental setups to study endothelial-hepatic para-
crine interactions. (Bi): Immunostaining for NFkB in unstimulated and IL-1b-stimulated hPSC-ECs, treatedwith orwithout quercetin and genistein.
NFkB, red; nucleus, blue. Scale bars = 100 mm. (Bii): Quantification of NFkB nuclear translocation shows that quercetin or genistein significantly
decreased levels of NFkB nuclear colocalization in coculture of hPSC-ECs with hPSC-HEPs. (C): IL-8 protein levels were significantly reduced in en-
dothelial-hepatic coculturebutnot in conditionedmedia setup. Statistical differenceswere comparedwith their respective stimulated groupswith-
outnutraceutical treatment.ppp,p # .001 (n=3 independentbiological replicates). Abbreviations:hPSC-ECs, humanpluripotent stemcell-derived
endothelial cells; hPSC-HEPs, human pluripotent stem cell-derived hepatocytes; IL, interleukin; NFkB, nuclear factor kB.
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Therefore, a coculture of hPSC-ECs and hPSC-HEPs could better
recapitulate the in vivo vascular-liver systemic interactome, with
renewal of metabolites by liver metabolism.
DISCUSSION
We have developed an endothelial-hepatic system to predict the
efficacy of nutraceuticals in vascular protection. Insights from de-
velopmental studies guided our hPSC differentiation strategy. We
established a protocol for efficient generation of functional endo-
thelial cells from a lateral plate mesoderm precursor. Endothelial
specification was induced by using FGF2, VEGF, and 1% O2, all of
which play roles in blood vessel development and angiogenesis
[57]. Furthermore, small-molecule SB431542, a potent antagonist
of activin receptor-like kinase, could enhance the efficiency of en-
dothelial differentiation by inhibiting TGF-b signaling [35], which
would otherwise promotemural cell specification frommesoderm.
ThesehPSC-ECswere responsive to IL-1b-stimulated inflammation,
but treatmentwitheitherquercetinor genisteinwasnot able tooff-
set the inflammatory activation. This was because of limited meta-
bolic activity of hPSC-ECs to break down the nutraceuticals into
bioactivemetabolites.Hence, it ledus topostulate thathepatocytes
from hPSCs possess metabolic capacity to enhance bioavailability of
metabolites from quercetin and genistein. We generated functional
hepatocytes according to our previously established protocol [15].
The hPSC-HEPs, with high expression of CYP enzymes, were able to
effectively metabolize quercetin and genistein into primary and sec-
ondary metabolites. Similar metabolites were detected when we
compared the nutraceutical treatment on our hPSC-HEPs with pri-
mary rat hepatocytes, as well as those metabolites described in pri-
mary human hepatocytes [24–28, 58, 59]. We recognize that the
primary rat hepatocytes required shorter time to metabolize the
parent nutraceutical, because they were freshly isolated and hence
could have retainedmost of their in vivo functionality. Depending
on the structural complexities, it is also likely that different nutra-
ceuticals would have distinct metabolic profiles. The hPSC-HEPs
may requiredifferent treatmentdurations to releaseoptimal levels
of metabolites. This also highlights the importance of dosage re-
sponse inhPSC-HEPs,wherearangeofphysiologically relevantcon-
centrations could be tested.
Incorporation of hepatocytes to endothelial culture under-
pins a key novelty of this work. Notably, hPSC-HEP-conditioned
media containing nutraceutical metabolites were not effective
in suppressing inflammation inhPSC-ECs. There couldbeadecline
in the potency of metabolites from hPSC-HEP-conditioned media
due to degradation. Instead, when hPSC-ECs were cocultured
with hPSC-HEPs in a shared medium, we noticed that there was
a significant reduction in inflammation. Continuous replenish-
mentofmetabolites in coculture setup recapitulated the systemic
setting of liver paracrine effects on the vasculatures. Conversely,
endothelial cells are known to improve hepatic function by pro-
moting cell viability, synthesis of albumin and urea, and efficiency
of thedrug transporter system[52–55].OurhPSC-ECscould, in turn,
increase the metabolizing CYP enzyme activity in hPSC-HEPs. An-
other advantage of this endothelial-hepatic crosstalk is to recapit-
ulate human-relevant response where certain drug metabolism
dynamicsmay not be accurately reproduced in animals [60]. Our
current system could still have limitations just as other in vitro
cell-based platforms. The need for evaluating chronic exposure
(i.e.,.3 weeks) to drugs will involve further optimization to en-
sure viability and sustainable functionality of cells in long-term
culture. For high-throughput drug-testing efforts, scalability of
hPSC-derived cells may require improved conditions, such as
supportive extracellular matrices or automation in bioreactors
[61–64], for robustness of production.
Multicellular coculture models [55, 65, 66] are gaining mo-
mentum for various applications. A recent study described the
use of human umbilical vein endothelial cells to stabilize hepa-
toblastoma C3A cells and modulate drug-induced hepatotoxic-
ity [56]. Endothelial cells from hPSCs were used to vascularize
liver constructs [52]. These are part of the advances to model
liver vasculatures, using multiple stromal cell types alongside
hepatocytes to develop liver lobule and sinusoid-like structures
[52–57, 65, 67–70], for hepatotoxicity screening and tissue-
engineering applications. We are the first to report a human stem
cell-derived endothelial-hepatic platform for efficacy testing of
complex compounds. Nonetheless, we could capitalize on our
endothelial-hepatic model for further development. Cells-on-
chip inmicrofluidic-basedsystemscouldprovidethebenefitsofdif-
ferent flow dynamics, minimizing reagents used, and optical
suitability for high-content imaging of cells. Initial studies showed
that endothelial cells [71, 72] and hepatocytes [17, 73] have im-
proved functionality in perfusion cultures. Phenotypic assays could
also be developed to capture different pathological readouts for
efficacy testing, aswell as toxicology assessment. A spectrumof as-
say endpoints for vascular injury and atherosclerosis may include
endothelial dysfunction, oxidative stress, apoptosis,matrix remod-
eling, etc. Multiplexing of phenotypic readouts in multicellular
models [17, 74] would add great value to the applications of cocul-
ture systems. In addition, our endothelial-hepatic platform could
be used for disease modeling involving paracrine crosstalk be-
tween liver and vasculature. Because the liver is integral to normal
or dysfunctional lipid homeostasis, this interplay could influence
vascular function [75]. Moreover, it is likely that lipid-modifying
nutraceuticals may involve liver metabolism to exert their actions
on vascular tissue.
CONCLUSION
Our hPSC-based endothelial-hepatic model represents a phys-
iologically relevant cellular system for nutraceutical screening,
enabled by the paracrine crosstalk between the two cell types.
Such a coculture system will help dissect the modes of actions
of complex compounds without the need to purify into their
constituent ingredients. Furthermore, this human-relevant plat-
form could enable mechanistic interrogation of candidate com-
pounds with liver- and vascular-targeting therapeutic effects or
toxicity prediction.
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